Gareth P Gregory

List of Publications by Year
in descending order

43 papers	1,505 citations	430874 18 h-index	330143 37 g-index
45 all docs	45 docs citations	45 times ranked	2817 citing authors

#	Article	IF	Citations
1	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 2022, 6, 1232-1242.	5.2	14
2	Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian singleâ€centre experience. Internal Medicine Journal, 2021, 51, 1825-1834.	0.8	0
3	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. Leukemia and Lymphoma, 2021, 62, 112-117.	1.3	5
4	Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood, 2021, 137, 2947-2957.	1.4	19
5	Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITDâ€“Driven Acute Myeloid Leukemia. Cancer Discovery, 2021, 11, 1582-1599.	9.4	35
6	Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. Journal of Personalized Medicine, 2021, 11, 355.	2.5	41
7	Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular Cell, 2021, 81, 2183-2200.e13.	9.7	59
8	<scp>COVID</scp>â€19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 2021, 51, 763-768.	0.8	12
9	Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH. Leukemia and Lymphoma, 2021, 62, 3060-3062.	1.3	1
10	The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell, 2021, 184, 3143-3162.e32.	28.9	103
11	Salvage radiotherapy associates with durable response for a subset of patients with limited stage refractory DLBCL. Blood Advances, 2021, 5, 5112-5115.	5.2	1
12	Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study. Targeted Oncology, 2021, 16, 761-771.	3.6	5
13	Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA). Blood, 2021, 138, 2532-2532.	1.4	0
14	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. Blood, 2021, 138, 181-181.	1.4	14
15	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. Blood, 2021, 138, 132-132.	1.4	15
16	Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance. Blood, 2021, 138, 882-882.	1.4	3
17	Diagnosis and management of primary central nervous system lymphoma: a Consensus Practice Statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 2021, , .	0.8	0
18	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia, 2020, 34, 1646-1657.	7.2	54

#	Article	IF	Citations
19	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. Clinical Cancer Research, 2020, 26, 6535-6549.	7.0	42
20	Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 997-1003.	2.3	8
21	Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. Journal of Physical Education and Sports Management, 2020, 6, a004994.	1.2	7
22	CDK13 cooperates with CDK12 to control global RNA polymerase II processivity. Science Advances, 2020, 6, .	10.3	79
23	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the <scp>COVID</scp>â€19 pandemic. Internal Medicine Journal, 2020, 50, 667-679.	0.8	37
24	Disseminated Lomentospora prolificans infection in a patient on idelalisib-rituximab therapy for relapsed chronic lymphocytic leukaemia. Annals of Hematology, 2020, 99, 2455-2456.	1.8	6
25	A consensus statement on the use of biosimilar medicines in hematology in Australia. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 211-221.	1.1	6
26	Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. Blood, 2020, 136, 42-44.	1.4	44
27	3002 â€“ REPROGRAMMING OF SERINE METABOLISM IS A METABOLIC VULNERABILITY IN FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTANT ACUTE MYELOID LEUKAEMIA. Experimental Hematology, 2020, 88, S37-S38.	0.4	0
28	Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large Bâ€cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. British Journal of Haematology, 2019, 187, 174-184.	2.5	23
29	Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. Nature Communications, 2019, 10, 1347.	12.8	41
30	AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA. Hematological Oncology, 2019, 37, 567-568.	1.7	2
31	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood, 2019, 134, 6-6.	1.4	152
32	An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies. Blood, 2019, 134, 1594-1594.	1.4	7
33	Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies. Blood, 2019, 134, 1548-1548.	1.4	7
34	Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2018, 182, 739-741.	2.5	1
35	Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications, 2018, 9, 5341.	12.8	356
36	Cold agglutinin disease complicated by acrocyanosis and necrosis. Annals of Hematology, 2017, 96, 509-510.	1.8	5

#	Article	IF	Citations
37	Genomic characterisation of EÎ¼-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene. Nature Communications, 2017, 8, 14581.	12.8	33
38	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics, 2016, 15, 2030-2041.	4.1	57
39	Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. Annals of Hematology, 2016, 95, 667-668.	1.8	18
40	The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Research, 2016, 76, 1158-1169.	0.9	100
41	Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma. Current Opinion in Hematology, 2014, 21, 297-308.	2.5	8
42	Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro-Oncology, 2013, 15, 1068-1073.	1.2	54
43	Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Annals of Hematology, 2011, 90, 989-990.	1.8	27